Claudio V.
- Country
- Italy
- Department
- Oncology
Research Overview
- Efficacy and Safety of Inavolisib plus Combination Therapy in Patients with Endocrine-Resistant HR+/HER2- Advanced Breast Cancer with Chromosome 8p Loss
- Comparison of RO7771950 plus combination therapy versus tucatinib plus combination therapy in pretreated HER2-positive locally advanced or metastatic breast cancer
- Dexamethasone Premedication to Prevent Grade ≥2 Interstitial Lung Disease in Breast Cancer Patients Receiving Trastuzumab Deruxtecan
Data & Insights
Has run more than one trial at 149 of 389 partner sites.
Specializations
Oncology Focus
This investigator specializes in the treatment of triple negative breast cancer, conducting research into innovative therapeutic approaches for this challenging breast cancer subtype.
- Breast Cancer Treatment
- Post-Surgical Therapy
- Immunotherapy Applications
Their work explores combination therapy strategies in the post-surgical setting for breast cancer patients.
Immunotherapy Research
The investigator's research centers on immunotherapeutic approaches in oncology, particularly focusing on treatment combinations involving pembrolizumab for breast cancer management.
- Novel Drug Combinations
- Immune-Based Treatments
- Treatment Response Assessment
Their expertise includes evaluating therapeutic efficacy in advanced cancer treatments.
Clinical Outcomes
The investigator studies invasive disease-free survival outcomes in cancer patients, with particular attention to treatment response evaluation in breast cancer therapy.
- Survival Analysis
- Treatment Comparison Studies
- Clinical Assessment Methods
Their research encompasses comparative analyses of different treatment approaches in oncology.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.